Literature DB >> 35484360

Serum lactate dehydrogenase as a novel prognostic factor for patients with primary undifferentiated pleomorphic sarcomas.

Qiaowei Lin1, Zhengwang Sun1, Lin Yu2, Qifeng Wang2, Ping Zhu2, Yihan Jiang3, Yangbai Sun4, Wangjun Yan5.   

Abstract

PURPOSE: Among soft tissue sarcomas, undifferentiated pleomorphic sarcoma (UPS) has relatively higher potential of recurrence and metastasis. As serum lactate dehydrogenase (LDH) is associated with tumor progression and unfavorable outcomes in multiple malignancies, we designed this study to explore the relationship between preoperative serum LDH and prognosis in UPS patients.
METHODS: We extracted the data of UPS patients who underwent primary surgery in Shanghai Cancer Center, Fudan University. Receiver-operating characteristic (ROC) curve was used to figure out the best cutoff value of LDH to classify them into high- or low-expression groups. Univariate and multivariate analyses were performed using Cox proportional hazards regression to identify independent prognostic factors. Kaplan-Meier analysis was used to compare differences in overall survival (OS) and time to recurrence (TTR) between patients with high- or low-serum LDH.
RESULTS: Multivariate analyses demonstrated that preoperative serum LDH was an independent factor for OS. Kaplan-Meier curves showed that patients with relatively high-serum LDH (P = 0.0004) had poorer OS compared with those with low-serum LDH. There was a trend that patients with relatively high-serum LDH had poorer TTR than those without (P = 0.1249). In addition, there were obvious trends that patients with decreased serum LDH after surgery showed better OS (P = 0.0954) and TTR (P = 0.1720) than those with elevated serum LDH. Moreover, high preoperative serum LDH was associated with female patients (P = 0.0004), positive margin (P < 0.0001), worse survival (P = 0.0061), higher mitotic index (P = 0.0222) and necrosis (P = 0.0225).
CONCLUSIONS: Preoperative serum LDH is an independent factor for OS in UPS patients, and it correlates with future surgical margin.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Lactate dehydrogenase; Long-term follow-up; Prognostic factor; Survival; Undifferentiated pleomorphic sarcomas

Year:  2022        PMID: 35484360     DOI: 10.1007/s00432-022-04014-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  53 in total

1.  Tumor cells hijack macrophages via lactic acid.

Authors:  Vincenzo Bronte
Journal:  Immunol Cell Biol       Date:  2014-08-05       Impact factor: 5.126

2.  Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis.

Authors:  Jian Chen; Meng-xiong Sun; Ying-qi Hua; Zheng-dong Cai
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-31       Impact factor: 4.553

3.  Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.

Authors:  Mitchell S Cairo; Richard Sposto; Mary Gerrard; Anne Auperin; Stanton C Goldman; Lauren Harrison; Ross Pinkerton; Martine Raphael; Keith McCarthy; Sherrie L Perkins; Catherine Patte
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

Authors:  Andrew J Armstrong; Daniel J George; Susan Halabi
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

Review 5.  Links between metabolism and cancer.

Authors:  Chi V Dang
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

6.  Prognostic significance of serum LDH in Ewing's sarcoma of bone.

Authors:  G Bacci; S Ferrari; A Longhi; S Rimondini; M Versari; A Zanone; C Forni
Journal:  Oncol Rep       Date:  1999 Jul-Aug       Impact factor: 3.906

7.  Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.

Authors:  Aileen M Davis; Brian O'Sullivan; Robert Turcotte; Robert Bell; Charles Catton; Pierre Chabot; Jay Wunder; Alex Hammond; Veronique Benk; Rita Kandel; Karen Goddard; Carolyn Freeman; Anna Sadura; Benny Zee; Andrew Day; Dongsheng Tu; Joseph Pater
Journal:  Radiother Oncol       Date:  2005-04       Impact factor: 6.280

8.  Lactate Dehydrogenase B Controls Lysosome Activity and Autophagy in Cancer.

Authors:  Lucie Brisson; Piotr Bański; Martina Sboarina; Coralie Dethier; Pierre Danhier; Marie-Joséphine Fontenille; Vincent F Van Hée; Thibaut Vazeille; Morgane Tardy; Jorge Falces; Caroline Bouzin; Paolo E Porporato; Raphaël Frédérick; Carine Michiels; Tamara Copetti; Pierre Sonveaux
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

9.  Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.

Authors:  Dario Callegaro; Rosalba Miceli; Sylvie Bonvalot; Peter Ferguson; Dirk C Strauss; Antonin Levy; Anthony Griffin; Andrew J Hayes; Silvia Stacchiotti; Cecile Le Pechoux; Myles J Smith; Marco Fiore; Angelo P Dei Tos; Henry G Smith; Luigi Mariani; Jay S Wunder; Raphael E Pollock; Paolo G Casali; Alessandro Gronchi
Journal:  Lancet Oncol       Date:  2016-04-05       Impact factor: 41.316

10.  Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.

Authors:  Janet E Brown; Richard J Cook; Allan Lipton; Robert E Coleman
Journal:  Clin Cancer Res       Date:  2012-09-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.